Prevention of preterm delivery after successful tocolysis in preterm labor by 17 alpha-hydroxyprogesterone caproate: A randomized controlled trial

Comparative Study to Assess the Efficacy Between Intramuscular and Vaginal Micronized Progesterone to Prevent Threatened Premature Labour

“…40 in France including 188 mothers analysis did not find a statistically significant difference between groups in the study's primary efficacy outcome, time to delivery (From randomization).…”

17 alpha-hydroxyprogesterone caproate does not prolong pregnancy or reduce the rate of preterm birth in women at high risk for preterm delivery and a short cervix: a randomized controlled trial

“…Two simultaneous studies assessed the efficacy of 17OHP-C among the following: (1) women admitted for an episode of preterm labor with intact membranes, successfully arrested by tocolytic treatment and a CL less than 25 mm, 24 and (2) asymptomatic twin pregnancies with a CL less than 25 mm. 25 An interim analysis of the results in this study was planned at their conclusion if recruitment in the trial reported here had not been completed.…”

“…This trial was planned as 1 part of a larger series of trials designed to evaluate the efficacy of intramuscular 17OHP-C in 3 groups of women at high risk of preterm birth. The other 2 groups were women with singleton pregnancies with tocolysis-arrested preterm labor 24 and patients with a CL less than 25 mm and those with asymptomatic twin 17P, 17 alpha-progesterone; Q 1 , first quartile; Q 3 , third quartile. a Estimated mean for censored data; b Gehan-Wilcoxon test.…”

Prevention of Preterm Birth - What Works and What Doesn’t?

“…While weekly IM injections of 17P has been shown to decrease the risk of recurrent preterm birth [5], it has been shown not to be beneficial in the setting of short cervix, twin gestation, or following preterm labor successfully arrested with tocolysis [6][7][8][9].…”

“…Rozenberg et al [9] Singleton, Preterm labor successfully arrested with tocolysis, CL<25mm 24-0/7 to 31-0/7 500mg twice weekly Given its ease of administration as compared to intramuscular progesterone, the use of vaginal progesterone in patients at risk for preterm birth may be preferred. While vaginal progesterone gel 90mg qam did not decrease risk of recurrent preterm birth in women with a prior spontaneous preterm birth [10], use of progesterone gel in singleton gestations with no history of preterm birth but with sonographically short cervix (10-20mm at 19 to 23-6/7 weeks) was found to reduce the incidence of preterm birth prior to 28, 33, and 35 weeks [11].…”